GH Research PLC (NASDAQ:GHRS) Receives $30.38 Consensus Price Target from Analysts

GH Research PLC (NASDAQ:GHRS) has been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $30.3750.

GHRS has been the subject of a number of recent research reports. JMP Securities reiterated a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a research note on Tuesday, June 24th. Needham & Company LLC started coverage on GH Research in a research report on Monday, October 13th. They issued a “buy” rating and a $19.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research note on Wednesday, October 8th. Wall Street Zen upgraded GH Research from a “sell” rating to a “hold” rating in a research note on Saturday, July 5th. Finally, Zacks Research cut GH Research from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th.

GH Research Stock Performance

Shares of GH Research stock opened at $14.00 on Friday. The stock has a market capitalization of $728.42 million, a P/E ratio of -18.92 and a beta of 0.97. GH Research has a 52-week low of $6.72 and a 52-week high of $20.50. The stock’s 50-day simple moving average is $13.31 and its 200 day simple moving average is $12.59.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. Equities research analysts forecast that GH Research will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GHRS. Palumbo Wealth Management LLC purchased a new position in shares of GH Research during the 1st quarter valued at $142,000. XTX Topco Ltd purchased a new position in GH Research during the first quarter worth about $169,000. Jefferies Financial Group Inc. purchased a new position in GH Research during the first quarter worth about $8,272,000. Walleye Capital LLC bought a new position in GH Research in the 1st quarter worth about $584,000. Finally, Troluce Capital Advisors LLC purchased a new stake in shares of GH Research in the 1st quarter valued at about $1,716,000. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).